Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3600)	4/26/2001 11:44:43 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

Peter re SCIO and p38. Scios is presenting the PIb portion next week in London at the new Anti-Arthritis Therapy Meeting (or something like that). The proper name is in the earnings PR. If it's good it will be a big deal as you note, because I don't think it's in many people's models even though PII is already planned. AdPRoTech is presenting on complement; if anyone is going grab a handout for me. Nigel, any chance? Incidentally, there were two questioners trying to shake some doubt/data loose about the % catheterized in the placebo vs. total treated population (which was 50/50). The issue had to do with bias in dyspnea self-analysis. I have to say I did not understand the concern and the company basically said we followed the FDA/protocol...but in one case the company just slammed the door shut on pursuing the inquiry---probably with good reason. Might be something to watch for in the report. I dunno. The second PIII seems so tight. Wilder